Table 3.
Characteristics of the subjects at baseline
| Placebo group (n=16) | Rosehip group (n=16) | |
|---|---|---|
| Age (year) | 50.6±13.7 | 50.1±9.2 |
| Height (cm) | 161.51±7.84 | 161.81±7.62 |
| Body weight (kg) | 70.01±8.36 | 70.31±6.19 |
| Body fat percent (%) | 31.34±4.93 | 30.56±6.96 |
| BMI (kg/m2) | 26.78±1.53 | 26.84±1.37 |
| Abdominal fat area (cm2) | ||
| Total | 305.35±59.45 | 286.61±44.46 |
| Subcutaneous | 200.39±61.95 | 197.94±56.45 |
| Visceral | 104.96±34.24 | 88.67±36.96 |
| SBP (mm-Hg) | 132.28±17.75 | 137.03±20.08 |
| DBP (mm-Hg) | 80.84±9.89 | 83.91±14.29 |
| FBS (mg/dL) | 88.7±10.7 | 83.9±7.7 |
| Cho (mg/dL) | ||
| Total-Cho | 205.1±25.7 | 210.1±25.7 |
| HDL-Cho | 60.3±11.6 | 55.8±9.2 |
| LDL-Cho | 126.8±23.6 | 137.4±21.8 |
Notes: Values represent the mean ± SD. There were no significant differences between the groups.
Abbreviations: BMI, body mass index; Cho, cholesterol; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.